Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study-Reference-Cited by-同舟云学术

Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study

Published:1996-10 Issue:3 Volume:39 Page:285-291
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Tr

Author:

Terenziani Monica,Demicheli Romano,Brambilla Cristina,Ferrari Laura,Moliterni Angela,Zambetti Milvia,Caraceni Augusto,Martini Cinzia,Bonadonna Gianni

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/BF01806156.pdf

Reference18 articles.

1. Debonis D, Terz JJ, Eldar Set al.: Survival of patients with metastatic breast cancer diagnosed between 1955 and 1980. J Surg Oncol 48: 158–163, 1991

2. Binet S, Fellous A, Lataste Het al.:In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16: 5–8, 1989

3. Besenval M, Delgado M, Demarez JPet al.: Safety and tolerance of Navelbine in phase I-II clinical studies. Semin Oncol 16: 37–40, 1989

4. Armand JP, Marty M: Navelbine: a new step in cancer therapy? Semin Oncol 16 (2) Suppl 4: 41–45, 1989

5. Cannobbio L, Boccardo F, Pastorino Get al.: Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 16 (Suppl 4): 33–36, 1989

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046;Journal of Cancer Research and Clinical Oncology;2021-03-20

2. Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer;Acta Oncologica;2020-12-01

3. Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer;Cancer Chemotherapy and Pharmacology;2019-12-14

4. The NAME trial: a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer;Future Oncology;2019-08

5. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer;Breast Cancer Research and Treatment;2014-01-09